Pharma Firm Inotiv Confirms Data Breach Following Ransomware Attack
## Data Breach at Inotiv Following Ransomware Incident
Data Breach at Inotiv Following Ransomware Incident
Inotiv, a contract research organization specializing in pharmaceutical drug discovery and development, reported a significant data breach resulting from a ransomware attack that occurred in early August 2025.
The company disclosed the incident in its fiscal 2025 financial results, indicating unauthorized access to critical systems between August 5 and August 8. The breach was discovered on August 8, 2025, and incident response procedures were immediately initiated.
Following the breach, Inotiv restored access to affected networks and systems and conducted a comprehensive forensic investigation. During the four-day compromise, attackers infiltrated the company's infrastructure, acquiring an unspecified amount of data. The exact scope and sensitivity of the exfiltrated information remain unclear.
Inotiv is providing notifications regarding the cybersecurity incident in line with applicable legal obligations, indicating that state and federal disclosure requirements are being addressed.
The company disclosed the incident in its fiscal 2025 financial results, indicating unauthorized access to critical systems between August 5 and August 8.
The full operational and financial impacts of the breach are still under evaluation. Inotiv has not yet determined if the incident will have material financial consequences. The breach compounds existing operational challenges, as the company faces substantial debt obligations totaling $402.1 million.
In fiscal 2025, Inotiv reported revenue of $513 million but posted an operating loss of $30.9 million. The company's financial guidance did not specify whether incident remediation costs would affect future earnings or were included in current loss projections.
The incident highlights cybersecurity risks in the pharmaceutical research sector, where organizations handle sensitive clinical data and proprietary drug development information. These factors make them attractive targets for threat actors.
Inotiv's disclosure aligns with broader ransomware trends targeting healthcare and pharmaceutical organizations, emphasizing the need for robust cybersecurity measures to protect high-value intellectual property and confidential client data.
Based on reporting by Cyber Security News.